MRNA stock

Is Moderna Inc (MRNA) undervalued? · rev $1.94B

Moderna Inc (MRNA) is a biotechnology company listed on NASDAQ. It is led by Stephane Bancel.

This page asks whether Moderna Inc (MRNA) looks cheap on cached numbers — not a DCF toy and not a buy alert.

Latest reported MRNA revenue for 2025-12-31 was $1.94B. Net income was -$2.82B. Revenue was down 39.9% from 2024-12-31 to 2025-12-31. MRNA currently screens at market cap $24.52B.

MRNA currently screens at market cap $24.52B. Cheap versus history or peers still needs a filing reason; a low multiple can be a value trap.

A new MRNA 10-Q can flip this screen overnight. The SEC page is the source.

Not investment advice. Compare MRNA to the stock page model before you treat a low multiple as a gift.

Not investment advice.

Full MRNA analysis